Press Releases

Intensity Therapeutics’ CEO, Lewis H. Bender, Named One of PharmaVOICE’s 100 Most Inspiring People for 2019

Aug 20 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of the company’s proprietary therapeutic agents, today announced that the July/August issue of the publication PharmaVOICE has named Lewis H. Bender, the Company’s Founder, President and CEO, as one of its 100 most inspiring people… Read more »

Intensity Therapeutics’ INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology

Jul 20 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of the company’s proprietary therapeutic agents, today announced the publication in the journal OncoImmunology of results from nonclinical research conducted in partnership with the National Cancer Institute’s (NCI) Vaccine Branch under a Cooperative Research and… Read more »

Intensity Therapeutics Announces Clinical Collaboration with Merck

Jun 20 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that it has entered into an agreement with Merck (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Intensity’s lead… Read more »

View All Press Releases

Publications/Papers/Posters

OncoImmunology July 16, 2019 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

Article published on-line July 16, 2019 in the journal OncoImmunology.  https://doi.org/10.1080/2162402X.2019.1625687 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. ABSTRACT The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a… Read more »

ASCO 2019 Poster Presentation – Abstract 2602

Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation  

SITC 2018 Poster Presentation P622

Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

View All Publications/Papers/Posters